The differential effects of nitrous oxide and xenon on extracellular dopamine levels in the rat nucleus accumbens: A microdialysis study

Anesthesia and Analgesia

Volumn 103, Issue 6, 2006, Pages 1459-1463

  Sakamoto, Sachiyo ^a   Nakao, Shinichi ^a   Masuzawa, Munehiro ^a   Inada, Takefumi ^a   Maze, Mervyn ^b,c   Franks, Nicholas P ^b,c   Shingu, Koh ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NITROUS OXIDE; OXYGEN; PENTOBARBITAL; XENON;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG EFFECT; EXTRACELLULAR MATRIX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MESOLIMBIC DOPAMINERGIC SYSTEM; MICRODIALYSIS; NEUROPSYCHOLOGY; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT;

ANIMALS; DOPAMINE; MALE; MICRODIALYSIS; NITRIC OXIDE; NUCLEUS ACCUMBENS; RATS; RATS, WISTAR; VENTRAL TEGMENTAL AREA; XENON;

EID: 33845662296     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ane.0000247792.03959.f1     Document Type: Article

References (25)

1. Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989;244:1360-2.
2. Löscher W, Hönack D. The behavioural effects of MK-801 in rats: involvement of dopaminergic, serotonergic and noradrenergic systems. Eur J Pharmacol 1992;215:199-208.
3. Franks NP, Dickinson R, de Sousa SLM, et al. How does xenon produce anesthesia [letter]? Nature 1998;396:324.
4. Jevtovic-Todorovic V, Todorovic SM, Mennerick S, et al. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nat Med 1998;4:460-3.
5. Dohrn CS, Lichtor JL, Coalson DW, et al. Reinforcing effects of extended inhalation of nitrous oxide in humans. Drug Alcohol Depend 1993;31:265-80.
6. 2O enhances ketamine-induced c-fos expression in the rat posterior cingulated and retrosplenial cortices. Anesth Analg 2001;92:362-8.
7. Ma D, Wilhelm S, Maze M, Franks NP. Neuroprotective and neurotoxic properties of the 'inert' gas, xenon. Br J Anaesth 2002;89:739-46.
8. Spanagel R, Weiss F. The dopamine hypothesis of reward: past and current status. Trends Neurosci 1999;22:521-7.
9. Takahashi S, Takagi K, Horikomi K. Effects of a novel, selective, sigma-1 ligand MS-377 on phencyclidine-induced behaviors. Naunyn Schmiedebergs Arch Pharmacol 2001;364:81-6.
10. Nishizawa N, Nakao S, Nagata A, et al. The effect of ketamine isomers on both mice behavioral responses and c-fos expression in the posterior cingulate and retrosplenial cortices. Brain Res 2000;857:188-92.
11. Mathe JM, Nomikos GG, Schilstrom B, Svensson TH. Non-NMDA excitatory amino acid receptors in the ventral tegmental area mediate systemic dizocilpine (MK801) induced hyperlocomotion and dopamine release in the nucleus accumbens. J Neurosci Res 1998;51:583-92.
12. Masuzawa M, Nakao S, Miyamoto E, et al. Pentobarbital inhibits ketamine-induced dopamine release in the rat nucleus accumbens: a microdialysis study. Anesth Analg 2003;96:148-52.
13. McCullough LD, Salamone JD. Increases in extracellular dopamine levels and locomotor activity after direct infusion of phencyclidine into the nucleus accumbens. Brain Res 1992;577:1-9.
14. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 2nd ed. San Diego: Academic Press, 1986.
15. Gonsowski CT, Eger EI II. Nitrous oxide minimum alveolar anesthetic concentration in rats is greater than previously reported. Anesth Analg 1994;79:710-12.
16. Koblin DD, Fang Z, Eger EI II, et al. Minimum alveolar concentrations of noble gases, nitrogen, and sulfur hexfluoride in rats: helium and neon as nonimmobilizers (nonanesthetics). Anesth Analg 1998;87:419-24.
17. French ED, Ceci A. Noncompetitive N-methyl-D-aspartate antagonists are potent activators of ventral tegmental A10 dopamine neurons. Neurosci Lett 1990;119:159-62.
18. Yamakura T, Harris RA. Effects of gaseous anesthetics nitrous oxide and xenon on ligand-gated ion channels. Anesthesiology 2000;93:1095-101.
19. Kawaguchi T, Mashimo T, Yagi M, et al. Xenon is another laughing gas. Can J Anaesth 1996;43:641-2.
20. Barr G, Jakobsson JG, Öwall A, Anderson RE. Nitrous oxide does not alter bispectral index: study with nitrous oxide as sole agent and as an adjunct to IV anaesthesia. Br J Anaesth 1999;82:827-30.
21. Goto T, Nakata Y, Saito H, et al. Bispectral analysis of the electroencephalogram does not predict responsiveness to verbal command in patients emerging from xenon anaesthesia. Br J Anaesth 2000;85:359-63.
22. Mansvelder HD, De Rover M, McGehee DS, Brussaard AB. Cholinergic modulation of dopaminergic reward areas: upstream and down stream targets of nicotine addiction. Eur J Pharmacol 2003;480:117-23.
23. Miller GW, Gainetdinov RR, Levey AI, Caron MG. Dopamine transporters and neuronal injury. Trends Pharmacol Sci 1999;20:424-9.
24. Sanders RD, Franks NP, Maze M. Xenon: no stranger to anaesthesia. Br J Anaesth 2003;91:709-17.
25. Aalto S, Ihalainen J, Hirvonen J, et al. Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharmacology 2005;182:375-83.